neutral effect on our fair value estimate, as we've stood by our belief that the drug is safe for approved uses. Karen Andersen BB&T's Credit Quality Remains Strong (Maintaining) BB&T BBT reported an excellent first quarter. The company
Karen Andersen : Baxter is a diversified health-care operation. They really operate in several different types of businesses. First, there
Fair Value Ratio*: 0.64 Morningstar analyst Karen Andersen thinks Vertex's VRTX expertise in chronic viral ..... significantly impact our Vectibix sales forecast. Karen Andersen Motorola Misses Forecasts Again (Maintaining) Motorola
teams focus on doing a better job in those two different verticals. Even though there might be some extra costs, Karen Andersen , whose is our Baxter analyst, thinks that overall this would probably be a pretty good deal. She's not planning
focused on the development of small molecule drugs for the treatment of infectious diseases. Morningstar analyst Karen Andersen expanded further on this commentary, noting that while she thinks that Gilead paid a steep premium to bring Pharmasset
company into leading positions in the antifungal, HIV, and hepatitis C markets. Morningstar health-care analyst Karen Andersen expects Gilead's returns on invested capital to return to the mid-20% range by 2017 and believes that Gilead
recently sat down with senior biotechnology analyst Karen Andersen to discuss Gilead Sciences GILD. A few weeks ago ..... terms of growth potential and patent protection? Karen Andersen , senior biotechnology analyst: Gilead started out
right now, and also to talk about some of their favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow
short term. More important, over the long term, we believe Crucell's vaccine platform and novel biologics manufacturing platform open the door to major new markets for Johnson & Johnson. Karen Andersen , CFA, contributed to this note.
AMGN, to emerge in the coming weeks. Given the timing of other acquisitions--such as Eli Lilly's LLY acquisition of ImClone--we think a deal could get done in September or October. Karen Andersen , CFA, contributed to this note.